Calendario›VTGN›PH94B
PH94B
Ensayo de Vistagen Therapeutics, Inc. en Adjustment Disorder With Anxious Mood (del registro, en inglés).
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 41
- Centros
- 2
- Fin del objetivo primario
- dic 2022
Título oficial en el registro (en inglés): PH94B in the Treatment of Adjustment Disorder With Anxiety
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, triple ciego. Comenzó en oct 2021.
De principio a fin
- Empieza el ensayo (oct 2021)
- Lectura de resultados dic 2022 (real)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Hamilton Anxiety Scale (HAM-A) Score (del registro, en inglés) (28 dias)
Qué se prueba
Estudio controlado con placebo que evalúa la eficacia, la seguridad y la tolerabilidad del spray nasal PH94B, administrado cuatro veces al día, como tratamiento del trastorno de adaptación con síntomas de ansiedad en adultos.
Lo que dice el documentoThis placebo-controlled clinical study is designed to evaluate the efficacy, safety and tolerability of administration of PH94B nasal spray four times per day as a treatment of Adjustment Disorder with Anxiety symptoms in adults. Subject participation in the Study will last a total of 6 to 10 weeks, depending on the duration of the screening period and whether they need a washout of concomitant anxiolytics.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis placebo-controlled clinical study is designed to evaluate the efficacy, safety and tolerability of administration of PH94B nasal spray four times per day as a treatment of Adjustment Disorder with Anxiety symptoms in adults. Subject participation in the Study will last a total of 6 to 10 weeks, depending on the duration of the screening period and whether they need a washout of concomitant anxiolytics. Upon signing an investigation review board approved informed consent, all subjects will complete Visit 1 (Screening) and enter a screening period lasting 7 to 35 days that could include taper of concomitant anxiolytics, if necessary. Screening visit will consist of safety assessments (medical history, physical examination, laboratory samples, electrocardiogram, urine drug screen, and urine pregnancy test [if appropriate]) and psychiatric assessments to determine eligibility. Subjects will then return to complete Visit 2 (Baseline). If the subject continues to meet inclusion and exclusion criteria, the subject will be randomized 1:1 to PH94B or placebo. Subjects will then commence 4 weeks of double-blind treatment with randomized investigational product (PH94B or placebo) four times per day. Subjects will return for weekly site visits (Visits 3, 4, 5, and 6), in which the subject will return the vial dispensed at the previous visit and receive a new vial, except at Visit 6 in which no new vial will be dispensed. Changes in AEs and concomitant medications will be collected. During these visits, psychiatric scales will be completed. When the subject returns for Visit 6, besides the assessments completed at Visits 3 through 5, the subjects will complete a brief physical examination, electrocardiogram, laboratory tests (chemistry and blood), and urinalysis. Any remaining IP vials will be collected. The subject will then come back after a one week washout period for Follow-up visit (Visit 7).
Más ensayos de VTGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Fasedienol Nasal Spray | Fase 2 | Completado | jun 2026 (real) |
| Fasedienol Nasal Spray · PALISADE-4 | Fase 3 | Completado | abr 2026 (real) |
| Fasedienol Nasal Spray · PALISADE-3 | Fase 3 | Completado | oct 2025 (real) |
| AV-101 | Fase 2 | Sin noticias del promotor | dic 2023 (prevista, ya pasada: sin actualizar en el registro) |
| PH94B | Fase 3 | Interrumpido | sep 2022 (real) |
| AV-101 | Fase 1 | Sin noticias del promotor | sep 2022 (prevista, ya pasada: sin actualizar en el registro) |
Todos los de VTGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04404192), actualizada en ene 2026.